Cargando…
Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor
Pleural effusion (PE) is a common manifestation of tuberculosis (TB) and malignant tumors but tuberculous PE (TPE) is difficult to distinguish from malignant PE (MPE), especially by noninvasive detection indicators. This study aimed to find effective detection indices in blood and PE for differentia...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575824/ https://www.ncbi.nlm.nih.gov/pubmed/36254028 http://dx.doi.org/10.1097/MD.0000000000031027 |
_version_ | 1784811396513398784 |
---|---|
author | Wang, Jian Feng, Zhe-Xiang Ren, Tao Meng, Wei-Yu Khan, Imran Fan, Xing-Xing Pan, Hu-Dan Liu, Liang Tang, Yi-Jun Yao, Xiao-Jun Li, Run-Ze Wang, Mei-Fang Leung, Elaine Lai-Han |
author_facet | Wang, Jian Feng, Zhe-Xiang Ren, Tao Meng, Wei-Yu Khan, Imran Fan, Xing-Xing Pan, Hu-Dan Liu, Liang Tang, Yi-Jun Yao, Xiao-Jun Li, Run-Ze Wang, Mei-Fang Leung, Elaine Lai-Han |
author_sort | Wang, Jian |
collection | PubMed |
description | Pleural effusion (PE) is a common manifestation of tuberculosis (TB) and malignant tumors but tuberculous PE (TPE) is difficult to distinguish from malignant PE (MPE), especially by noninvasive detection indicators. This study aimed to find effective detection indices in blood and PE for differentiating TB from a malignant tumor. A total of 815 patients who were diagnosed with TB or cancer in Hubei Shiyan Taihe Hospital from 2014 to 2017 were collected. Amongst them, 717 were found to have PE by thoracoscopy. Clinical characteristics, patients’ blood parameters and PE indicator information were summarized for analysis. Patients with MPE had higher percentages to be bloody and negative of Rivalta test in PE than those with TPE. For clinical indicators, comparison of the specific parameters in blood showed that 18 indicators were higher in the TPE group than in the MPE group. By contrast, 12 indicators were higher in the MPE group than in the TPE group (P < .01). In addition, in PE tests, 3 parameters were higher in the TPE group, whereas other 4 parameters were higher in the MPE group (P < .01). Then, for clinical diagnosing practice, ROC analysis and principal component analysis were applied. The top 6 relevant indicators with area under curve over 0.70 were screened out as follows: hydrothorax adenosine dehydrogenase (pADA, 0.90), hydrothorax high-sensitivity C reactive protein (0.79), percentage of blood monocyte (sMONp, 0.75), blood high-sensitivity C reactive protein (sHsCRP, 0.73), erythrocyte sedimentation rate (0.71) and blood D-dimer (0.70). Moreover, logistic regression model revealed that a specific combination of 3 biomarkers, namely, pADA, sMONp and sHsCRP, could enhance the distinguishment of TB from malignant tumor with PE (area under curve = 0.944, 95% confidence interval = 0.925–0.964). The diagnostic function of the top single marker pADA in patients from different groups was analyzed and it was found to maintain high specificity and sensitivity. The 6 indicators, namely, pADA, hydrothorax high-sensitivity C reactive protein, sMONp, sHsCRP, sESR and blood D-dimer, showed significant diagnostic value for clinicians. Further, the combination of pADA, sMONp and sHsCRP has high accuracy for differential diagnosis for the first time. Most interestingly, the single marker pADA maintained high specificity and sensitivity in patients with different statuses and thus has great value for rapid and accurate diagnosis of suspected cases. |
format | Online Article Text |
id | pubmed-9575824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95758242022-10-17 Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor Wang, Jian Feng, Zhe-Xiang Ren, Tao Meng, Wei-Yu Khan, Imran Fan, Xing-Xing Pan, Hu-Dan Liu, Liang Tang, Yi-Jun Yao, Xiao-Jun Li, Run-Ze Wang, Mei-Fang Leung, Elaine Lai-Han Medicine (Baltimore) 5700 Oncology Pleural effusion (PE) is a common manifestation of tuberculosis (TB) and malignant tumors but tuberculous PE (TPE) is difficult to distinguish from malignant PE (MPE), especially by noninvasive detection indicators. This study aimed to find effective detection indices in blood and PE for differentiating TB from a malignant tumor. A total of 815 patients who were diagnosed with TB or cancer in Hubei Shiyan Taihe Hospital from 2014 to 2017 were collected. Amongst them, 717 were found to have PE by thoracoscopy. Clinical characteristics, patients’ blood parameters and PE indicator information were summarized for analysis. Patients with MPE had higher percentages to be bloody and negative of Rivalta test in PE than those with TPE. For clinical indicators, comparison of the specific parameters in blood showed that 18 indicators were higher in the TPE group than in the MPE group. By contrast, 12 indicators were higher in the MPE group than in the TPE group (P < .01). In addition, in PE tests, 3 parameters were higher in the TPE group, whereas other 4 parameters were higher in the MPE group (P < .01). Then, for clinical diagnosing practice, ROC analysis and principal component analysis were applied. The top 6 relevant indicators with area under curve over 0.70 were screened out as follows: hydrothorax adenosine dehydrogenase (pADA, 0.90), hydrothorax high-sensitivity C reactive protein (0.79), percentage of blood monocyte (sMONp, 0.75), blood high-sensitivity C reactive protein (sHsCRP, 0.73), erythrocyte sedimentation rate (0.71) and blood D-dimer (0.70). Moreover, logistic regression model revealed that a specific combination of 3 biomarkers, namely, pADA, sMONp and sHsCRP, could enhance the distinguishment of TB from malignant tumor with PE (area under curve = 0.944, 95% confidence interval = 0.925–0.964). The diagnostic function of the top single marker pADA in patients from different groups was analyzed and it was found to maintain high specificity and sensitivity. The 6 indicators, namely, pADA, hydrothorax high-sensitivity C reactive protein, sMONp, sHsCRP, sESR and blood D-dimer, showed significant diagnostic value for clinicians. Further, the combination of pADA, sMONp and sHsCRP has high accuracy for differential diagnosis for the first time. Most interestingly, the single marker pADA maintained high specificity and sensitivity in patients with different statuses and thus has great value for rapid and accurate diagnosis of suspected cases. Lippincott Williams & Wilkins 2022-10-14 /pmc/articles/PMC9575824/ /pubmed/36254028 http://dx.doi.org/10.1097/MD.0000000000031027 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 5700 Oncology Wang, Jian Feng, Zhe-Xiang Ren, Tao Meng, Wei-Yu Khan, Imran Fan, Xing-Xing Pan, Hu-Dan Liu, Liang Tang, Yi-Jun Yao, Xiao-Jun Li, Run-Ze Wang, Mei-Fang Leung, Elaine Lai-Han Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor |
title | Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor |
title_full | Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor |
title_fullStr | Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor |
title_full_unstemmed | Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor |
title_short | Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor |
title_sort | novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor |
topic | 5700 Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575824/ https://www.ncbi.nlm.nih.gov/pubmed/36254028 http://dx.doi.org/10.1097/MD.0000000000031027 |
work_keys_str_mv | AT wangjian novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT fengzhexiang novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT rentao novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT mengweiyu novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT khanimran novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT fanxingxing novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT panhudan novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT liuliang novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT tangyijun novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT yaoxiaojun novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT lirunze novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT wangmeifang novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor AT leungelainelaihan novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor |